TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20874458
Drug: Fluticasone propionate/salmeterol
Normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate/salmeterol (FP/S) 500/50 μg
Study: 18688066
Drug: Double-dose sirolimus-eluting
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Double-dose sirolimus-eluting stents (SES) (280 microg/cm2)
Study: 18688066
Drug: Single-dose sirolimus-eluting
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-dose sirolimus-eluting stents (SES) (140 microg/cm2)
Study: 11220982
Drug: Sildenafil 10
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 10 mg
Study: 9973007
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg digoxin
Study: 9973007
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg diltiazem‐CD
Study: 9973007
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg digoxin + 240 mg diltiazem‐CD
Study: 9973007
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg digoxin + 50 mg atenolol
Study: 8475955
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of aspirin
Study: 2183591
Drug: Golytely (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golytely (standard polyethylene glycol-based lavage solution)
Study: 77993
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment application
Study: 23641793
Drug: Oral levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levofloxacin 500 mg 1*1 for 21 days
Study: 17218327
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy plus ultrasound (US)
Study: 17218327
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy plus placebo ultrasound (placebo US)
Study: 11145762
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (biventricular pacing)
Study: 8240146
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline infusion adjusted to maintain therapeutic levels.
Study: 8240146
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received nebulised salbutamol and ipratropium bromide, intravenous hydrocortisone, and oxygen.
Study: 3927692
Drug: CoQ10 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (150 mg/day in 3 daily doses) for 4 weeks
Study: 26681678
Drug: trabectedin 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: trabectedin 1.3 mg/mq i.v. q 3 weeks
Study: 17549328
Drug: Intramuscular stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular stimulation
Study: 15308432
Drug: Antianginal medications
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal medications (beta-blockers, calcium antagonists, long-acting nitrates)
Study: 15308432
Drug: Antianginal medications
Normalized name: ANTIANGINALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antianginal medications prescribed
Study: 9842806
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion 100 microg kg(‐1) min(‐1) (n = 29)
Study: 7695326
Drug: Fluconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (400 mg/day)
Study: 162672
Drug: ibuprofen (900‐1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen (900‐1800 mg/day)
Study: 162672
Drug: indomethacin (75‐150
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin (75‐150 mg/day)
Study: 19013758
Drug: Daily 16-week
Normalized name: futibatinib
DrugBank: Futibatinib (DB15149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 16-week home-based hand exercise
Study: 16625231
Drug: Cabergoline (0.5‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline (0.5‐1 mg weekly for 6 months)
Study: 11769817
Drug: Clozapine 6
Normalized name: clozapine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 6 mg
Study: 11769817
Drug: Clozapine 3
Normalized name: clozapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 3 mg
Study: 11769817
Drug: Clozapine 3
Normalized name: clozapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 3 mg and 6 mg
Study: 9231677
Drug: External irradiation
Normalized name: CATHETER,EXTERNAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: External irradiation alone (planned dose 60 Gy)
Study: 8220800
Drug: Double-blind placebo-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind placebo-controlled challenge with gelatine capsules
Study: 3690941
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg acetaminophen plus 60 mg codeine
Study: 22898215
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg every other week for 12 weeks)
Study: 21116022
Drug: n-3 long-chain
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 long-chain polyunsaturated fatty acids (LCPUFA) supplementation (600 mg EPA and 400 mg DHA)
Study: 15674155
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral antibiotics for 2 weeks followed by oral antibiotics for 4 weeks (Group I)
Study: 10765510
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel in the morning
Study: 10765510
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 gel in the evening
Study: 8774203
Drug: Ardeparin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ardeparin (low-molecular-weight heparin), 0.005 mL/kg (50 anti-Xa U/Kg), administered subcutaneously twice daily for 14 days or until discharge.
Study: 8774203
Drug: Placebo (graduated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (graduated compression stockings alone), administered subcutaneously twice daily for 14 days or until discharge.
Study: 8774203
Drug: Ardeparin (low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ardeparin (low-molecular-weight heparin)
Study: 6338868
Drug: 4',6-Dichloroflavan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4',6-Dichloroflavan (1 mg/kg, 3 times per day for 3 doses before and 13 doses after challenge)
Study: 25549767
Drug: Planning-focused cognitive
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Planning-focused cognitive behavioral therapy (CBT)
Study: 25549767
Drug: Solution-focused treatment
Normalized name: undecylenate Topical Solution [Hongo Killer Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused treatment (SFT)
Study: 21816474
Drug: Comparison group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison group (monthly case management plus referrals to community services)
Study: 18070948
Drug: Cooled ablation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled ablation (open irrigation at 15 ml/min, 45 degrees C, 35 (5) W)
Study: 12373659
Drug: Gabapentin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (up to 1,800 mg/day)
Study: 2402214
Drug: Inosine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine supplementation (6,000 mg.d‐1 for 2 d)
Study: 7446607
Drug: Intrauterine irrigation
Normalized name: Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine irrigation with cefamandole nafate solution
Study: 7446607
Drug: Irrigation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irrigation with normal saline solution
Study: 26860124
Drug: Vorapaxar monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorapaxar monotherapy
Study: 20412603
Drug: Single 200,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200,000 IU vitamin A capsule administration
Study: 19227864
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy containing a specialized product enriched with vitamins and minerals (50% calcium, 20% protein, 17-60% of 11 minerals, and 11 vitamins)
Study: 15704058
Drug: Bosentan (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (500 mg twice daily, titrated slowly or rapidly)
Study: 15846939
Drug: Cuban trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuban trivalent inactivated vaccine against human leptospirosis (vax‐SPIRAL)
Study: 15846939
Drug: Russian-made vaccine
Normalized name: Russian thistle pollen extract
DrugBank: Salsola kali pollen (DB10388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Russian-made vaccine
Study: 10350029
Drug: Alprazolam 2
Normalized name: alprazolam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 2 mg during the midluteal phase of the menstrual cycle
Study: 10350029
Drug: Alprazolam 2
Normalized name: alprazolam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 2 mg during the midfollicular phase of the menstrual cycle
Study: 1760833
Drug: Intravenous isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isosorbide dinitrate (ISDN) at a dose of 10 mg/h over the first 3 days of infarction
Study: 1760833
Drug: Anticoagulants only
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulants only
Study: 7333402
Drug: 8-methoxypsoralen solution
Normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-methoxypsoralen solution
Study: 7333402
Drug: Commercial solid
Normalized name: Corydalis solida whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial solid formulations of 8-methoxypsoralen
Study: 31359271
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of oral risperidone
Study: 31359271
Drug: Dose adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose adjustment of risperidone by -25% for poor metabolizers and by -10% for intermediate metabolizers
Study: 19090549
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement containing EPA (33 patients)
Study: 10720131
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) alfa treatment
Study: 1413984
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (0; 1.12; 2.24; 3.37 g n-3 FA/day)
Study: 1413984
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (3.37 g n-3 FA/day)
Study: 3863197
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg PGE2 triacetin gel administered twice over a 12 hour period
Study: 3863197
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg PGE2 triacetin gel administered as a single dose
Study: 21940729
Drug: Eplerenone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone therapy for 24 weeks
Study: 19423946
Drug: 1,800 mg
Normalized name: daratumumab-hyaluronidase-fihj 1,800 mg-30,000 unit/15 mL SUBCUT VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,800 mg of eicosapentaenoic acid (EPA) + statin
Study: 14628190
Drug: Zydis Selegiline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zydis Selegiline 5 mg
Study: 8061382
Drug: Triple-dose gadoteridol
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple-dose gadoteridol (0.3 mmol/kg total: 0.1 mmol/kg + 0.2 mmol/kg)
Study: 8061382
Drug: Single-dose gadoteridol
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose gadoteridol (0.1 mmol/kg)
Study: 31741283
Drug: Preservative-free hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free hydrocortisone 0.335% for 12 days four times daily followed by 2 days twice daily instillation (intense treatment group)
Study: 31741283
Drug: Preservative-free hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free hydrocortisone 0.335% for 8 days three times daily followed by 3 days twice daily treatment (standard treatment group)
Study: 28612179
Drug: CT-P10 1000
Normalized name: Tums 750 MG 8 ct - 1000 72 ct Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P10 1000 mg
Study: 28612179
Drug: RTX 1000
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX 1000 mg
Study: 26730183
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium (TIO) 18 mcg
Study: 18771373
Drug: Clarithromycin, 500
Normalized name: Clarithromycin, 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin, 500 mg, every 12 hours for six doses
Study: 12204968
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) 600 mg/day, Nelfinavir (NFV) 750 mg three times daily, Stavudine (d4T) 30 or 40 mg twice daily
Study: 12204968
Drug: Efavirenz (EFV),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (EFV), Nelfinavir (NFV), and Stavudine (d4T) therapy
Study: 9097333
Drug: Structured empowerment
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured empowerment programme with a trained psychologist during 20 weekly 1-hour sessions
Study: 8412364
Drug: Butyrate suppositories
Normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butyrate suppositories
Study: 8412364
Drug: Glutamine suppositories
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine suppositories
Study: 8412364
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional therapy for pouchitis discontinued)
Study: 24398824
Drug: Quetiapine extended-release
Normalized name: Quetiapine Extended-Release Tablets
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine extended-release (XR) (50 to 300 mg daily)
Study: 24398824
Drug: Amitriptyline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (10 to 75 mg daily)
Study: 25653826
Drug: Quetiapine extended-release
Normalized name: Quetiapine Extended-Release Tablets
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine extended-release (XR)
Study: 22349808
Drug: Amuvatinib LSC
Normalized name: Amuvatinib
DrugBank: Amuvatinib (DB12742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amuvatinib LSC (single-dose)
Study: 22349808
Drug: Amuvatinib LSC
Normalized name: Amuvatinib
DrugBank: Amuvatinib (DB12742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amuvatinib LSC 300 mg every 8 h (multiple-dose)
Study: 20297950
Drug: Fenofibrate (145
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (145 mg NanoCrystal tablet)
Study: 20597872
Drug: Low-dose transpupillary
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transpupillary thermotherapy (TTT)
Study: 15664306
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (8 g per day)
Study: 15664306
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (placebo, 8 g per day)
Study: 12452875
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream 3 days per week with occlusion
Study: 12452875
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream 3 days per week without occlusion
Study: 10328192
Drug: Topical sucralfate
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical sucralfate 4 times a day for 3 months
Study: 7585833
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g daily for 10 days)
Study: 8417865
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 2 mg daily
Study: 8417865
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 2 mg daily after placebo
Study: 3542091
Drug: Deflazacort (DFL)
DrugBank: Deflazacort (DB11921)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Deflazacort (DFL) 24 mg/day
Study: 3542091
Drug: Prednisone (Pd)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (Pd) 20 mg/day
Study: 19842011
Drug: Modafinil (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (titrated up to a maximum of 400 mg/day over 4 weeks)
Study: 16022951
Drug: 10-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-microg dose in the 30-day release group
Study: 16022951
Drug: 30-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-microg dose in the 30-day release group
Study: 12459617
Drug: Atraumatic restorative
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atraumatic restorative treatment (ART) using glass-ionomer
Study: 9550353
Drug: CDP-choline (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (500 mg daily for 10 days every six months)
Study: 9550353
Drug: CDP-choline plus
Normalized name: CDP-choline
DrugBank: Citicoline (DB12153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline plus one hour of occlusion daily
Study: 9550353
Drug: One hour
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One hour of occlusion daily
Study: 1835334
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus two preoperative and three postoperative intralesional injections of triamcinolone
Study: 1835334
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus oral colchicine (1.2 mg per day) initiated 3 weeks after surgery and continued for 5 months
Study: 7027655
Drug: Topical Clobetasol-17-propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Clobetasol-17-propionate
Study: 7027655
Drug: Other topical
Normalized name: Other topical products for joint and muscular pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other topical corticoids
Study: 28793974
Drug: GSK561679 (CRF1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679 (CRF1 receptor antagonist)
Study: 25855926
Drug: Urinary kallidinogenase
Normalized name: kallidinogenase
DrugBank: Kallidinogenase (DB13197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary kallidinogenase (0.15 PNAU/d, for 7 days) after rt‐PA (0.9 mg/kg)
Study: 25855926
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received rt‐PA (0.9 mg/kg)
Study: 11703991
Drug: Eptifibatide (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (0.75 dose)
Study: 11703991
Drug: Eptifibatide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (0.5 dose)
Study: 9743925
Drug: Heparin 2
Normalized name: heparin 2 units/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 2 U/ml saline flush solution
Study: 9743925
Drug: Heparin 10
Normalized name: heparin 10 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 10 U/ml saline flush solution
Study: 9743925
Drug: Saline flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline flush solution
Study: 23759263
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ALA-P plus 1.8 mg iron
Study: 18391135
Drug: Ondansetron (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.50 mg)
Study: 18391135
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of naltrexone and ondansetron
Study: 16670166
Drug: T(4)‐T(3) combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(4)‐T(3) combination therapy
Study: 11093363
Drug: Iloperidone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone (8 mg/day to 32 mg/day)
Study: 1433880
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia with droperidol, fentanyl and ketamine (DFK)
Study: 2987601
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg megestrol acetate (MA)
Study: 2987601
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg megestrol acetate (MA)
Study: 2987601
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg megestrol acetate (MA)
Study: 2987601
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg megestrol acetate (MA)
Study: 2987601
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA) equivalent dosages 1000-1500 mg
Study: 24576857
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) supplementation (1200 mg·d)
Study: 18076534
Drug: Antidepressant (AD)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant (AD) treatment
Study: 18076534
Drug: No Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Antidepressant (non-users)
Study: 10480613
Drug: N(G)‐monomethyl‐L‐arginine (L‐NMMA);
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)‐monomethyl‐L‐arginine (L‐NMMA); total dose 5 mg/kg body weight